What you should know:
1. Bone Biologics concluded a preclinical study of rhNELL-1. Researchers found the product was well tolerated with no inflammation.
2. Bone Biologics intends to build on the preclinical results and launch a clinical trial at a later date.
3. Researchers tested the rhNELL-1 product on sheep, finding increases in fusion and quantity of bone when compared to a control.
4. Bone Biologics received approval to test rhNELL-1 on 30 patients in Australia in a multicenter pilot clinical trial.
More articles on biologics:
Dr. Bryan Little appointed to state medical board, task force
Former Medtronic, Bioventus executive becomes CEO at BlueWind Medical
Exactech co-founders retire, current CEO to transition to board role — 4 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
